NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) ACpaclitaxel (P) plus gemcitabine (G) with DD ACP and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer

This article has no abstract
Epistemonikos ID: 217ba4a3d1875d54981cc9c33a5c26d25e0b80e5
First added on: Feb 05, 2025